product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Phospho-Rb (Ser807/811) Antibody
catalog :
9308L
quantity :
300 ul
price :
658 USD
clonality :
polyclonal
host :
rabbit
antigen modification :
phosphorylated
reactivity :
human, mouse, rat
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section
more info or order :
Cell Signaling Technology product webpage
citations: 20
Published Application/Species/DilutionReference
  • western blot; human; fig 2
Xi Z, Yao M, Li Y, Xie C, Holst J, Liu T, et al. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. Cell Death Dis. 2016;7:e2252 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:50; fig s1
Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed publisher
  • western blot; human; 1:500; fig s5
Hong A, Tseng Y, Cowley G, Jonas O, Cheah J, Kynnap B, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016;7:11987 pubmed publisher
  • western blot; human; fig 1
Meng F, Qian J, Yue H, Li X, Xue K. SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase. Cell Cycle. 2016;: pubmed
  • western blot; mouse
Yousuf M, Tan C, Torres-Altoro M, Lu F, Plautz E, Zhang S, et al. Involvement of aberrant Cdk5/p25 activity in experimental traumatic brain injury. J Neurochem. 2016;: pubmed publisher
  • western blot; human; fig 5
Nakayama R, Zhang Y, Czaplinski J, Anatone A, Sicinska E, Fletcher J, et al. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016;7:16581-92 pubmed publisher
  • western blot; human; 1:1000; fig 6
Lee W, Jo S, Lee M, Won C, Lee M, Choi J, et al. The Effect of MCP-1/CCR2 on the Proliferation and Senescence of Epidermal Constituent Cells in Solar Lentigo. Int J Mol Sci. 2016;17: pubmed publisher
  • western blot; human; fig 2
Perumal D, Kuo P, Leshchenko V, Jiang Z, Divakar S, Cho H, et al. Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Res. 2016;76:1225-36 pubmed publisher
  • immunohistochemistry; mouse; 1:300; fig 1
Lanza D, Dawson E, Rao P, Heaney J. Misexpression of cyclin D1 in embryonic germ cells promotes testicular teratoma initiation. Cell Cycle. 2016;15:919-30 pubmed publisher
  • western blot; human; 1:1000; fig 3C
Kang M, Park K, Yang J, Lee C, Oh S, Yun J, et al. miR-6734 Up-Regulates p21 Gene Expression and Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Cells. PLoS ONE. 2016;11:e0160961 pubmed publisher
  • western blot; human; fig 6
Lee N, Kwon J, Kim Y, Kim S, Park S, Xu W, et al. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition. Oncotarget. 2015;6:30130-48 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:200; fig 3
Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt A, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. 2015;6:21522-32 pubmed
  • immunocytochemistry; human
  • western blot; human; 1:1000
Tanaka T, Iino M. Knockdown of Sec8 promotes cell-cycle arrest at G1/S phase by inducing p21 via control of FOXO proteins. FEBS J. 2014;281:1068-84 pubmed publisher
  • western blot; human; 1:500
Malaviya A, Sylvester P. Synergistic Antiproliferative Effects of Combined γ -Tocotrienol and PPAR γ Antagonist Treatment Are Mediated through PPAR γ -Independent Mechanisms in Breast Cancer Cells. PPAR Res. 2014;2014:439146 pubmed publisher
  • western blot; human; 1:1000
Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159:176-87 pubmed publisher
  • western blot; human; 1:1000
Muenyi C, Trivedi A, Helm C, States J. Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells. Toxicol Sci. 2014;139:74-82 pubmed publisher
  • western blot; human; fig 5
Sappino A, Buser R, Seguin Q, Fernet M, Lesne L, Gumy-Pause F, et al. The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage. Oncogenesis. 2012;1:e7 pubmed publisher
Yamakoshi K, Katano S, Iida M, Kimura H, Okuma A, Ikemoto-Uezumi M, et al. Dysregulation of the Bmi-1/p16(Ink⁴a) pathway provokes an aging-associated decline of submandibular gland function. Aging Cell. 2015;14:616-24 pubmed publisher
Abrahám E, Miskolczi P, Ayaydin F, Yu P, Kotogány E, Bako L, et al. Immunodetection of retinoblastoma-related protein and its phosphorylated form in interphase and mitotic alfalfa cells. J Exp Bot. 2011;62:2155-68 pubmed publisher
Zheng Y, Zhang H, Zhang X, Feng D, Luo X, Zeng C, et al. MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene. 2012;31:80-92 pubmed publisher
product information
SKU :
9308L
Product-Name :
Phospho-Rb (Ser807/811) Antibody
Size :
300 ul
Price-(USD) :
658 USD
Species-x-Reactivity :
H, R, Mk, (M)
Applications :
Immunohistochemistry (Paraffin)
Product-Category :
Cell Cycle / Checkpoint Control
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Polyclonal Antibody
MW :
110
Host :
Rabbit
Target :
Rb (Ser807/Ser811) phosphate
Primary-Protein :
Rb
Alt-Names :
OSRC,RB1,Rb,Retinoblastoma-associated protein,p105-Rb,pRb,pp110,retinoblastoma 1,retinoblastoma suspectibility protein
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.